VEGFR-2-IN-73 是一种强效且高选择性的 VEGFR-2 抑制剂,其对 VEGFR-2 的抑制作用(IC50 = 0.0787 μM)显著优于对 EGFR 的抑制作用(IC50 = 1.31 μM),在多种癌细胞系中均表现出强大的抗增殖活性,可诱导 G2/M 期和 Pre-G1 期细胞周期阻滞并显著促进细胞凋亡(apoptosis),可用于结直肠癌、肝细胞癌和乳腺癌等抗癌领域的研究。
VEGFR-2-IN-73
产品编号: MS-R98025 分子式: C29H29N5O3S2 分子量: 559.70
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

VEGFR-2-IN-73 是一种强效且高选择性的 VEGFR-2 抑制剂,其对 VEGFR-2 的抑制作用(IC50 = 0.0787 μM)显著优于对 EGFR 的抑制作用(IC50 = 1.31 μM),在多种癌细胞系中均表现出强大的抗增殖活性,可诱导 G2/M 期和 Pre-G1 期细胞周期阻滞并显著促进细胞凋亡(apoptosis),可用于结直肠癌、肝细胞癌和乳腺癌等抗癌领域的研究。

生物实验数据

生物活性 VEGFR-2-IN-73 is a potent and highly selective VEGFR-2 inhibitor whose inhibitory effect on VEGFR-2 (IC50 = 0.0787 μM) is significantly superior to that on EGFR (IC50 = 1.31 μM); it exhibits strong antiproliferative activity across multiple cancer cell lines, induces G2/M and Pre-G1 phase cell cycle arrest and markedly promotes apoptosis, and can be used in anticancer research including colorectal cancer, hepatocellular carcinoma, and breast cancer.
IC50 & Target

VEGFR-2

0.0787 μM (IC50)

体外研究
(In Vitro)

VEGFR-2-IN-73 (compound 15) (2 天) 对 HCT-116、HepG-2 和 MCF-7 癌细胞系表现出强细胞毒性 (IC50 分别为 3.66、3.31 和 4.29 μM),而对正常 WI-38 细胞则表现出极小的细胞毒性 (IC50 > 69 μM),显示出良好的选择性特征。
VEGFR-2-IN-73 (3.31-4.29 μM,72 小时) 可有效诱导 HCT-116、HepG-2 和 MCF-7 细胞的 G2/M 期和 Pre-G1 期周期阻滞,并显著触发细胞凋亡,其作用与 Doxorubicin (HY-15142A) 相当。
VEGFR-2-IN-73 与 VEGFR-2 的预测结合能 (-24.27 kcal/mol) 远低于Sorafenib (MS-X92288) (-20.88 kcal/mol),显示出更优的结合亲和力。

Cell Cycle Analysis

Cell Line: HCT-116, HepG-2, and MCF-7 Cells
Concentration: 3.66, 3.31, and 4.29 μM for HCT-116, HepG-2, and MCF-7 Cells, respectively
Incubation Time: 72 h
Result: Induced a significant increase in the Hep-G2 cell population in the G2/M (from 12.73% to 38.49%) and Pre-G1 (from 1.92% to 22.80%) phases.
Induced a significant increase in the HCT-116 cell population in the G2/M (from 5.45% to 22.72%) and Pre-G1 (from 1.91% to 16.05%) phases.
Significantly increased the population of MCF-7 Cells in the G2/M and Pre-G1 phases from 9.55% and 2.14% to 31.58% and 14.29%, respectively.
Reduced the proportion of cells in the G0-G1 and S phases compared to the control in Hep-G2, HCT-116, and MCF-7 cell lines.

Apoptosis Analysis

Cell Line: HCT-116, HepG-2, and MCF-7 Cells
Concentration: 3.66, 3.31, and 4.29 μM for HCT-116, HepG-2, and MCF-7 Cells, respectively
Incubation Time: 72 h
Result: Induced a total apoptosis rate of 16.05% in HCT-116 cells (early: 5.64%; late: 8.72%).
Induced a total apoptosis rate of 22.8% in HepG-2 cells (early: 6.38%; late: 13.9%).
Induced a total apoptosis rate of 14.29% in MCF-7 cells (early: 5.86%; late: 6.77%).
Triggered apoptosis in HCT-116, HepG-2, and MCF-7 Cells, with an efficacy comparable to Doxorubicin.

化学信息

分子量 559.70
分子式 C29H29N5O3S2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础